RNS Number: 6040 F GlaxoSmithKline PLC 15 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6039 F GlaxoSmithKline PLC 15 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6036 F GlaxoSmithKline PLC 15 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5494 F GlaxoSmithKline PLC 15 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Drugs group GlaxoSmithKline has announced "positive results" from Phase 3 trials of its Zejula treatment as a maintenance therapy for ovarian cancer patients following chemotherapy. It says the results show “significant improvement in progression-free survival” in the women taking the treatment.

GlaxoSmithKline Plc (GSK.L) Announced positive results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in patients with first-line ovarian cancer following platinum-based chemotherapy. The study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status. The safety and tolerability profile of niraparib was consistent with previous clinical trials. Niraparib is marketed in the United States and Europe under the trade name ZEJULA®.

RNS Number: 4559 F GlaxoSmithKline PLC 15 July 2019. Issued: 15 July 2019, London UK- LSE announcement. GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA for patients with ovarian cancer in the first line maintenance setting.

RNS Number: 4559 F GlaxoSmithKline PLC 15 July 2019. Issued: 15 July 2019, London UK- LSE announcement. GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA for patients with ovarian cancer in the first line maintenance setting.

RNS Number: 4374 F GlaxoSmithKline PLC 12 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 4344 F GlaxoSmithKline PLC 12 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

GlaxoSmithKline Plc (GSK.L) Announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, revealed positive Week 48 results from its phase III TANGO study. The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate (TAF)- containing regimen of at least three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen (2DR) of dolutegravir plus lamivudine in a fixed dose combination, compared to continuing the TAF-containing regimen. The safety results for the 2DR of dolutegravir plus lamivudine were consistent with the product labelling for the medicines. Full results from the study will be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019), to be held from 21-24 July in Mexico City

RNS Number: 1391 F GlaxoSmithKline PLC 10 July 2019 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study. Full results from the study will be presented at the 10 th International AIDS Society Conference on HIV Science, to be held from 21-24 July in Mexico City.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study. Full results from the study will be presented at the 10 th International AIDS Society Conference on HIV Science, to be held from 21-24 July in Mexico City.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study. Full results from the study will be presented at the 10 th International AIDS Society Conference on HIV Science, to be held from 21-24 July in Mexico City.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study. Full results from the study will be presented at the 10 th International AIDS Society Conference on HIV Science, to be held from 21-24 July in Mexico City.

RNS Number: 0093 F GlaxoSmithKline PLC 10 July 2019 Issued: 10 July 2019, London UK- LSE Announcement. London, UK, 10 July 2019- ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study. Full results from the study will be...

Deborah Waterhouse, CEO, ViiV Healthcare, said:“ For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. With around 25,000 new HIV diagnoses in Europe* every year 2, and the fact that today HIV is considered a chronic condition which requires people living with HIV to remain on antiretroviral...

Deborah Waterhouse, CEO, ViiV Healthcare, said:“ For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. With around 25,000 new HIV diagnoses in Europe* every year 2, and the fact that today HIV is considered a chronic condition which requires people living with HIV to remain on antiretroviral...

RNS Number: 2765 E GlaxoSmithKline PLC 03 July 2019 Issued: 3 July 2019, London UK- LSE Announcement. Deborah Waterhouse, CEO, ViiV Healthcare, said: "For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. With around 25,000 new HIV diagnoses in Europe every year, and the fact that t oday HIV is...